How to Cite
Abstract
Parkinson´s Disease is the most common movement disorder and the second most frequent neurodegenerative disease in the Central Nervous System (CNS). It predominates in men and the usual age of presentation is between 65 and 70 years old. Neuropathology involves dopamine depleted levels, secondary to cytoplasmic inclusions of alpha-Synuclein. Cardinal motor symptoms correspond to bradykinesia, rest tremor and rigidity. Non motor symptoms have been described, the most recognized at the prodrome are anosmia, constipation and sleep disturbances. The diagnosis is made clinically, the International Parkinson and Movement Disorder Society (MDS) provides some criteria that can guide it. The main biomarker identified is the alfa-Synuclein. Pharmacological therapy is based on Levodopa preparations, dopaminergic agonists and monoamino oxidase inhibitors.
Keywords
References
Ropper AH, Samuels MA, Klein J. Adams and Victor’s principles of neurology. Eleventh edition. New York: McGraw-Hill Education; 2019. 1 p.
Chen-Plotkin AS, Zetterberg H. Updating Our Definitions of Parkinson’s Disease for a Molecular Age. Brundin P, Langston JW, Bloem BR, editores. J Park Dis. 18 de diciembre de 2018;8(s1):S53-7.
Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. agosto de 2017;124(8):901-5.
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. noviembre de 2016;15(12):1257-72.
Cerri S, Mus L, Blandini F. Parkinson’s Disease in Women and Men: What’s the Difference? J Park Dis. 30 de julio de 2019;9(3):501-15.
Raza C, Anjum R, Shakeel N ul A. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci. junio de 2019;226:77-90.
Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. enero de 2018;46:S30-3.
Cheong SL, Federico S, Spalluto G, Klotz K-N, Pastorin G. The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy. Drug Discov Today. septiembre de 2019;24(9):1769-83.
Homayoun H. Parkinson Disease. Ann Intern Med. 4 de septiembre de 2018;169(5):ITC33-48.
Reichmann H. Premotor Diagnosis of Parkinson’s Disease. Neurosci Bull. octubre de 2017;33(5):526-34.
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. julio de 2017;18(7):435-50.
Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 11 de febrero de 2020;323(6):548.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease: MDS-PD Clinical Diagnostic Criteria. Mov Disord. octubre de 2016;30(12):1591-601.
Caproni S, Colosimo C. Diagnosis and Differential Diagnosis of Parkinson Disease. Clin Geriatr Med. febrero de 2020;36(1):13-24.
Cova I, Priori A. Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? J Neural Transm. octubre de 2018;125(10):1417-32.
Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, et al. Parkinson’s disease biomarkers based on α‐synuclein. J Neurochem. septiembre de 2019;150(5):626-36.
Klietz M, Greten S, Wegner F, Höglinger GU. Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients. Drugs Aging. junio de 2019;36(6):511-30.
Reich SG, Savitt JM. Parkinson’s Disease. Med Clin North Am. marzo de 2019;103(2):337-50.
Mak MKY, Wong-Yu ISK. Exercise for Parkinson’s disease. En: International Review of Neurobiology [Internet]. Elsevier; 2019 [citado 26 de octubre de 2021]. p. 1-44. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0074774219300212
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2022 Array